RNAC Key Statistics, Chart & Performance
The current stock price of RNAC is 7.16 USD. In the past month the price increased by 12.52%. In the past year, price decreased by -62.3%.
RNAC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RNAC. When comparing the yearly performance of all stocks, RNAC is a bad performer in the overall market: 91.68% of all stocks are doing better.
RNAC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RNAC. RNAC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RNAC Financial Highlights
Over the last trailing twelve months RNAC reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS increased by 83.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.58% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RNAC Forecast & Estimates
15 analysts have analysed RNAC and the average price target is 36.28 USD. This implies a price increase of 406.74% is expected in the next year compared to the current price of 7.16.
For the next year, analysts expect an EPS growth of 79.52% and a revenue growth -95.06% for RNAC
RNAC Ownership
About RNAC
Company Profile
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Company Info
CARTESIAN THERAPEUTICS INC
7495 New Horizon Way
Frederick MARYLAND US
Employees: 66
Phone: 13013488698
CARTESIAN THERAPEUTICS INC / RNAC FAQ
What does CARTESIAN THERAPEUTICS INC do?
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Can you provide the latest stock price for CARTESIAN THERAPEUTICS INC?
The current stock price of RNAC is 7.16 USD. The price decreased by -1.65% in the last trading session.
Does CARTESIAN THERAPEUTICS INC pay dividends?
RNAC does not pay a dividend.
What is the ChartMill rating of CARTESIAN THERAPEUTICS INC stock?
RNAC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is CARTESIAN THERAPEUTICS INC (RNAC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RNAC.
How many employees does CARTESIAN THERAPEUTICS INC have?
CARTESIAN THERAPEUTICS INC (RNAC) currently has 66 employees.
Can you provide the market cap for CARTESIAN THERAPEUTICS INC?
CARTESIAN THERAPEUTICS INC (RNAC) has a market capitalization of 186.16M USD. This makes RNAC a Micro Cap stock.